Use of mismatch repair immunohistochemistry and microsatellite instability testing: Exploring Canadian practices

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 560-569

  Kalloger, Steve E ^a   Allo, Ghassan ^d   Mulligan, Anna Marie ^b   Pollett, Aaron ^c   Aronson, Melyssa ^c   Gallinger, Steven ^d   Torlakovic, Emina E ^d   Clarke, Blaise Alexander ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

colon cancer; endometrial cancer; Lynch syndrome; microsatellite instability; mismatch repair deficiency

Indexed keywords

ARTICLE; CANADA; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNET; METHODOLOGY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NEOPLASM; PROFESSIONAL PRACTICE; PROGNOSIS; QUESTIONNAIRE; STATISTICS; UTILIZATION REVIEW;

CANADA; DNA MISMATCH REPAIR; HUMANS; IMMUNOHISTOCHEMISTRY; INTERNET; MICROSATELLITE INSTABILITY; NEOPLASMS; PROFESSIONAL PRACTICE; PROGNOSIS; QUESTIONNAIRES;

EID: 84859099475     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31823f3b28     Document Type: Article

References (25)

1. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.
2. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010;138:2197 e1-e7.
3. Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med. 2011;13:356-360.
4. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408-3415.
5. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
6. Hewish M, Lord CJ, Martin SA, et al. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010;7:197-208.
7. Kievit W, de Bruin JH, Adang EM, et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet. 2004;65: 308-316.
8. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer. Ann Int Med. 2011;155:69-79.
9. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010;17:235-248.
10. Mojtahed A, Schrijver I, Ford JM, et al. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24:1004-1014.
11. Movahedi-Lankarani SGC, Soslow R, Oliva E. Protocol for the examination of specimens from patients with carcinoma of the endometrium. http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2011/ Endometrium-11protocol.pdf.
12. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42-65.
13. Remick SC, Grem JL, Fischer PH, et al. Phase I trial of 5- fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res. 1990;50:2667-2672.
14. Resnick K, Straughn JM Jr. Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol. 2009;114:530-536.
15. Resnick KE, Hampel H, Fishel R, et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114:128-134.
16. Ryan P, Mulligan AM, Aronson M, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer. 2011. doi: 10.1002/cncr.26323. [Epub ahead of print].
17. Sanchez JA, Vogel JD, Kalady MF, et al. Identifying Lynch syndrome: we are all responsible. Dis Colon Rectum. 2008;51:1750-1756.
18. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as firstline screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33:1639-1645.
19. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781-789.
20. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009;11:3-14.
21. Torlakovic EE, Riddell R, Banerjee D, et al. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol. 2010;133:354-365.
22. Turner JWBF, Bloom SK, Cooper TJ, et al. Prognostic uses of MSI testing. http://www.cap.org/apps/docs/committees/technology/ microsatellite-testing.pdf.
23. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424-425.
24. Vasen HF, Moslein G, Alonso A, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer. 2007;9:109-115.
25. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25: 118-145.